Two Sigma Investments LP Sells 57,599 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Two Sigma Investments LP lessened its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 424,537 shares of the company's stock after selling 57,599 shares during the quarter. Two Sigma Investments LP owned 0.54% of Viridian Therapeutics worth $8,138,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in VRDN. R Squared Ltd acquired a new position in Viridian Therapeutics in the fourth quarter worth approximately $26,000. Foresite Capital Management VI LLC bought a new stake in Viridian Therapeutics in the fourth quarter worth approximately $38,000. AlphaQuest LLC grew its position in Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after acquiring an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in shares of Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after purchasing an additional 1,516 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth $164,000.

Viridian Therapeutics Stock Performance

Shares of NASDAQ:VRDN traded down $0.13 during midday trading on Friday, hitting $13.84. The company's stock had a trading volume of 88,876 shares, compared to its average volume of 1,187,027. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The stock's 50 day simple moving average is $13.04 and its 200 day simple moving average is $16.55. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -3.21 and a beta of 0.57. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business's revenue was up .0% on a year-over-year basis. As a group, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VRDN has been the subject of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Royal Bank of Canada reduced their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and set a $36.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. The Goldman Sachs Group lowered their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, JMP Securities reduced their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, Viridian Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $36.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.